Traumatic flexor tendon injuries.

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Abstract

[Indexed for MEDLINE] 18. Am J Hematol. 2022 Aug;97(8):1055-1064. doi: 10.1002/ajh.26576. Epub 2022 Jun 20. Burden of disease, treatment utilization, and the impact on education and employment in patients with sickle cell disease: A comparative analysis of high- and low- to middle-income countries for the international Sickle Cell World Assessment Survey. Osunkwo I(1), James J(2), El-Rassi F(3), Nero A(4), Minniti CP(5), Trimnell C(6), Paulose J(7), Ramscar N(8), Bailey T(9), Rajkovic-Hooley O(9), Andemariam B(10). Author information: (1)Sickle Cell Disease Enterprise, The Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA. (2)Sickle Cell Society, London, UK. (3)Emory University School of Medicine and Georgia Comprehensive Sickle Cell Center at Grady Health System, Atlanta, Georgia, USA. (4)University of Texas Southwestern Medical Center, Dallas, Texas, USA. (5)Albert Einstein College of Medicine, New York, New York, USA. (6)Sickle Cell 101, San Jose, California, USA. (7)Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. (8)Novartis Pharma AG, Basel, Switzerland. (9)Adelphi Real World, Bollington, UK. (10)New England Sickle Cell Institute, University of Connecticut Health, Farmington, Connecticut, USA. The international Sickle Cell World Assessment Survey (SWAY) reported a high impact of sickle cell disease (SCD) on patients' daily lives globally. In this study, we analyzed whether the reported burden differed between patients from the USA (n = 384) and other high-income (HI; n = 820) or low- to middle-income (LMI; n = 941) countries. We assessed symptoms and complications, incidence/management of vaso-occlusive crises (VOCs), treatment utilization/satisfaction, and the impact of SCD on education/employment. Certain symptoms (bone aches, insomnia, and joint stiffness) and complications (swollen/painful fingers/toes, gallstones, vision problems, blood clots, and asthma) were reported proportionally more by patients in the USA than in the HI/LMI countries. Self-reported VOCs were more common (mean [SD]: 7.1 [5.7] vs. 5.5 [8.9] and 4.4 [4.6] in the previous 12 months) and were managed more often by hospitalization (52% vs. 24% and 32%) in the USA than the HI and LMI countries. A higher proportion of patients from the USA than the HI/LMI countries reported a negative impact of SCD on their employment/schooling. Although high overall satisfaction with current treatments was reported globally, most patients indicated a strong desire for alternative pain medications. There are likely several reasons for the relatively high patient-reported burden in the USA group compared with the HI/LMI countries, including an older population and differences in newborn screening programs and pediatric/adult transition of care. It is clear that there is an urgent need for improved understanding and management of SCD globally, not just in the USA. © 2022 Novartis Pharmaceuticals. American Journal of Hematology published by Wiley Periodicals LLC. DOI: 10.1002/ajh.26576 PMCID: PMC9540420